AU2018282427C1 — Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Assigned to Glaxo Group Ltd · Expires 2022-06-30 · 4y expired
What this patent protects
A composition comprising a compound of the formula: 0 N X OH Compound (1) wherein X- is a pharmaceutically acceptable anion; and a compound of the formula: HOCH2 C HO CHCH 2NH(CH 2)6O(CH2)2OCH2 OH C or a pharmaceutically acceptable salt thereof (Compound (I1)).
USPTO Abstract
A composition comprising a compound of the formula: 0 N X OH Compound (1) wherein X- is a pharmaceutically acceptable anion; and a compound of the formula: HOCH2 C HO CHCH 2NH(CH 2)6O(CH2)2OCH2 OH C or a pharmaceutically acceptable salt thereof (Compound (I1)).
Drugs covered by this patent
- Arnuity Ellipta (FLUTICASONE FUROATE) · Haleon Us Holdings
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.